Xceleron and Servier have announced that they have signed a twelve-month rolling Collaborative Agreement.
The Agreement covers the provision by Xceleron of accelerator mass spectrometry (AMS) services to assist Servier in taking candidate drugs into humans much earlier than conventional Phase 1 studies.
This Agreement is the first of its kind whereby a pharma company is altering its traditional discovery/development processes to accommodate early human studies as part of the drug candidate selection processes.
Professor Colin Garner, Xceleron's CEO commented, "This collaborative Agreement is the result of Servier and Xceleron working together for a number of years to use the AMS technology to accelerate drug development."
"It shows the far-sightedness of Servier in introducing novel enabling technologies to change their paradigm of drug development".
Dr Bernard Marchand, Servier's Director of Biopharmacy commented, "we are delighted to be working with Xceleron who have pioneered the human Phase 0 microdose approach."
"Our positive experience as one of the supporters of the CREAM trial has enabled us to see the potential utility of AMS in improving our drug selection procedures".